Evidence map›Paper›PMID 40614191›Full record

ArticleScience advances2025

Discovery of an autoinhibited conformation in mesotrypsin reveals a strategy for selective serine protease inhibition.

Matt Coban, Mahesh Gokara, Luis M Forero Vargas, Sarah D Tanzer, Sherry X Zhou, Alexandra Hockla, Banumathi Sankaran, Thomas R Caulfield, Evette S Radisky

Abstract read
In one paragraph

Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Matt CobanDepartment of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0001-6396-6759
Mahesh GokaraDepartment of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0001-7095-887X
Luis M Forero VargasDepartment of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA.
Sarah D TanzerDepartment of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA.
Sherry X ZhouDepartment of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0002-8390-099X
Alexandra HocklaDepartment of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA.ORCID 0009-0007-7179-5671
Banumathi SankaranDivision of Molecular Biophysics and Integrated Bioimaging, Berkeley Center for Structural Biology, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.ORCID 0000-0002-3266-8131
Thomas R CaulfieldDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0002-1055-3069
Evette S RadiskyDepartment of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0003-3121-109X

Funding

User Training and OutreachP30GM124169 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI Gregory L Hura · 2017 to 2026
$28.6M
Exploiting new approaches for selective inhibition of trypsinsR01GM144393 · NIGMS · MAYO CLINIC JACKSONVILLE · PI Evette S Radisky · 2022 to 2026
$1.5M
NIGMS NIH HHS P30 GM124169NIGMS NIH HHS R01 GM144393
6 · The paper itself

Abstract

Selective inhibition of the more than 100 S1 family serine proteases is a long-standing challenge due to their active site similarity. Mesotrypsin, implicated in cancer progression, exemplifies these difficulties; no current inhibitors achieve selectivity over other human trypsins. We found an unexpected autoinhibited conformation of mesotrypsin via x-ray crystallography, revealing a cryptic pocket adjacent to the active site. Using high-throughput virtual screening targeting this cryptic pocket, we identified a conformationally selective small-molecule inhibitor that stabilizes the inactive state of mesotrypsin. This inhibitor demonstrates selectivity for mesotrypsin over other trypsins. Our findings challenge the accepted view of digestive trypsins as constitutively active enzymes lacking potential for allosteric regulation. Furthermore, analyses of other structures suggest that dynamic sampling of closed states with analogous allosteric cryptic pockets appears widespread among S1 serine proteases. These observations point to a potentially generalizable strategy to achieve selective inhibition, offering broad implications for drug development targeting serine proteases in cancer and other diseases.

Indexed as

Serine Proteinase InhibitorsTrypsinAllosteric RegulationCatalytic DomainCrystallography, X-RayHumansModels, MolecularProtein ConformationSerine ProteasesPRSS3 protein, humanSerine ProteasesSerine Proteinase InhibitorsTrypsin

Identifiers

PMID40614191
PMCPMC12227052

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.